TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1805-R1 and NVP-1805-R2

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female adults aged 19-45 years.~* BMI of \>18.5 kg/㎡ and \<27.0 kg/㎡ subject, weight more than 50kg.~* Voluntarily provided a witten consent to participate in this clinical study.~Exclusion Criteria:~* Treatment with an investigational product (Phase I study or Biological study) within 3month preceeding the first dose of study medication.~* History of (or presence) study medication absortion, distribution, metabolism(e.g., liver/ductal, kidney, cardio-vascular, endocrine, respiratory, GI, hematology, oncology, CNS, musculo-skeletal) or related past medical/surgery history~* Pregnant or lactating women.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- NVP-1805-R1 (Type: EXPERIMENTAL): Drug: NVP-1805-R1~1 tablet, oral dosing
- NVP-1805-R2 (Type: EXPERIMENTAL): Drug: NVP-1805-R2~1 tablet, oral dosing
- NVP-1805-R1 and NVP-1805-R2 (Type: EXPERIMENTAL): Drug: NVP-1801-R1 1 tablet and NVP-1801-R2 1 tablet co-administration(oral dosing)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open Label Study To Assess The Effectiveness Of Amlodipine-Atorvastatin Combination In Hypertension And Dyslipidemia.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Treated or untreated subjects with concurrent hypertension and dyslipidemia with BP and LDL-C not at target according to governing guidelines~Exclusion Criteria:~* High liver enzymes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Obese Hypertension Study (0954-315)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Obese male and female patients, ages 21-75 years, with high blood pressure~Exclusion Criteria:~* Patients cannot have any other severe cardiac conditions

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Losartan
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Mycobacterium w in Patients With Severe Sepsis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients with severe sepsis within 48 hours of first organ dysfunction~* Cardiovascular system dysfunction: systolic blood pressure ≤90 mm Hg or the mean arterial pressure ≤70 mm Hg for at least one hour despite adequate fluid resuscitation or the use of vasopressors to maintain a systolic blood pressure or mean arterial pressure of \>90 and \>65 mm Hg, respectively~* Renal dysfunction: urine output \<0.5 ml/kg/hour for two consecutive hours despite adequate fluid resuscitation~* Respiratory system dysfunction: PaO2/FiO2 ≤300 or ≤250 if lung sepsis~* Hematologic dysfunction: platelet count \<100,000/mm3 or decrease by 50% in the three days preceding enrollment~* Unexplained metabolic acidosis: pH ≤7.30~Exclusion Criteria:~* Pregnancy~* Gram-positive culture~* Only fungal infection as source of sepsis~* Patients who received cardiopulmonary resuscitation~* Those on immunosuppressive therapy~* Those unwilling to provide informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Mycobacterium w group (Type: EXPERIMENTAL): Patients in the experimental arm (Mw) in addition to standard care will receive single daily dose of 0.3 mL of Mw (heat-inactivated Mw \[0.5 × 10\^9\]; Cadila Pharma, Ahmedabad, India) in the deltoid region for 3 consecutive days
- Best standard care (Type: ACTIVE_COMPARATOR): Best standard care for sepsis

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Detecting an Early Response to Donepezil With Measures of Visual Attention

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of Alzheimer's Disease~* Mini Mental State Examination score \>15 / 30~* Can swallow pills~Exclusion Criteria:~* No other dementia due to Parkinson's disease, Lewy Body dementia, Normal Pressure Hydrocephalus, Fronto-temporal dementia, or prominent cerebral vascular accident~* No prior or concurrent use of cholinesterase inhibitors~* No prior or concurrent use of memantine hydrochloride~* No other concurrent anticholinergic treatments

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 95 Years
- Healthy Volunteers: f

Study Arms:
- Drug (Type: EXPERIMENTAL): Participants in the Drug group received oral 5mg of Donepezil Hydrochloride daily for 6 months. The Drug group was assessed at baseline, after approximately 6 weeks and after 6 months of treatment. The baseline to 6 weeks phase was part of the double-blind, placebo controlled portion of the trial.
- Placebo (Type: PLACEBO_COMPARATOR): Participants in the placebo group first received oral administration of a placebo pill for approximately 6 weeks. After that initial interval, the study was unblinded and participants in the placebo group then received 5mg of donepezil hydrochloride treatment for 6 months.~The Placebo group was evaluated at baseline, after 6 weeks of placebo, after 6 weeks of donepezil hydrochloride drug treatment, and 6 months of donepezil hydrochloride treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Investigating the Absolute Oral Bioavailability of Balovaptan After Single and Multiple Daily Oral Doses of Balovaptan in Healthy Volunteers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy male and female subjects. Healthy status is defined by absence of evidence of any active or chronic disease following a detailed medical and surgical history, a complete physical examination including vital signs, 12-lead ECG, hematology, blood chemistry, urinalysis, and serology.~* Body Mass Index of 18 to 30 kg/m2, inclusive.~* For women of childbearing potential: agreement to use at least 2 acceptable contraceptive methods during the treatment period and for 90 days after the last dose of study drug.~* For men: agreement to use contraceptive measures, and agreement to refrain from donating sperm until 90 days after the last dose of study drug.~Exclusion Criteria:~* Female subjects who are pregnant or lactating.~* Any condition or disease detected during the medical interview/physical examination that would render the subject unsuitable for the study, place the subject at undue risk or interfere with the ability of the subject to complete the study in the opinion of the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Participants received the study drug at dose level A in 2 periods. There was a minimum of a 14-day wash out period between Day 1 of Period 1 and Day 1 of Period 2.
- Cohort 2 (Type: EXPERIMENTAL): Participants received the study drug at dose level B in 2 periods. There was a minimum of a 14-day wash out period between Day 1 of Period 1 and Day 1 of Period 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Vagus Nerve Stimulation: Integration of Behavior and Cardiac Modulation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: Recurrent MDD diagnosis (≥ 2 episodes) with a current active depressive episode.~Exclusion Criteria:~* History of Axis I psychiatric diagnosis other than MDD or anxiety disorder - e.g., substance use disorder, psychotic disorder, or bipolar disorder.~* Current Suicidal Ideation with intent and/or plan or history of suicide attempt within the last year~* Use of psychotropic medications within four weeks prior to study with the exception of Selective Serotonin Reuptake Inhibitors (SSRIs) and Selective Norepinephrine Reuptake Inhibitors (SNRIs) class of antidepressant medication only~* Use of Tricyclic antidepressants (TCAs), Monoamine oxidase inhibitors (MAOIs), and Atypical agents~* History of cardiovascular disease~* History of neuroleptic use~* Past history of substance abuse or dependence within the past 12 months (excludes nicotine)~* Bleeding disorder or use of anticoagulants.~* Pregnancy~* Metallic implants or devices contraindicating magnetic resonance imaging.~* Use of beta blockers

- Gender: FEMALE
- Minimum Age: 25 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Exhalatory-gated tVNS (Type: EXPERIMENTAL): exhalatory-gated tVNS on the left auricle
- Inhalatory-gated tVNS (Type: ACTIVE_COMPARATOR): inhalatory-gated tVNS on the left auricle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Promoting Physical Activity in Churchgoing Latinas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between the ages of 18-65 years of age~* Latino~* Must be a member of a participating church for at least six months~* Live within 10-15 minutes driving distance from the church~* Able to travel to the church during the week~* Able to attend activities at the church during the week~* Attend church activities (worship or otherwise) at least 4 times a month~* Plan on living in same residence for the next 24 months~* Engage in less than 150 minutes of moderate-to-vigorous physical activity per week~Exclusion Criteria:~* Attendance at other churches participating in the study~* Must not have any conditions limiting ability to be physically active~* Pregnant

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Physical activity (Type: EXPERIMENTAL): Latinas exposed to multi-level Faith in Action intervention promoting physical activity.
- Cancer screening (Type: ACTIVE_COMPARATOR): Latinas exposed to Faith in Action intervention on cancer screening and prevention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must have a diagnosis of open angle glaucoma (OAG) or ocular hypertension (OH) in one or both eyes.~* IOP requirements at Visit 3, A mean/median IOP ≥ 26 mmHg at a minimum of 1 time point, ≥ 24 mmHg at a minimum of 1 time point, and ≥ 22 mmHg at 1 time point in the same eye, and Mean/median IOP ≤ 32 mmHg in both eyes at all 3 measurement time points.~* Subjects with best-corrected visual acuity (BCVA), using Early Treatment of Diabetic Retinopathy Study (ETDRS) protocol, of +0.7 logMAR units (Snellen equivalent \~20/100) or better in either eye.~Exclusion Criteria:~* Subjects with a known hypersensitivity or contraindications to latanoprost or any of the ingredients in the study drugs.~* Subjects with known contraindications to nitric oxide (NO) treatment.~* Subjects whose central corneal thickness was greater than 600um in either eye.~* Subjects with any condition that prevented reliable applanation tonometry in either eye.~* Subjects with advanced glaucoma and subjects with a cup/disc ratio greater than 0.8 or a history of split fixation, or a field loss threatening fixation in either eye.~* Subjects with previous or active corneal disease.~* Subjects with a history of severe dry eye.~* Subjects with monophthalmia.~* Subjects with optic disc hemorrhage.~* Subjects with a history of central retinal vein and artery occlusion.~* Subjects with a history of macular edema.~* Subjects with any intraocular infection, inflammation, or laser surgery within the previous 6 months from Visit 1 (Screening).~* Subjects who had incisional ocular surgery or severe trauma within the previous 6 months from Visit 1 (Screening).~* Subjects with very narrow angles (3 quadrants with less than Grade 2 according to Shaffer's anterior chamber angle grading system) and subjects with angle closure, congenital and secondary glaucoma, and subjects with history of angle closure in either eye.~* Subjects with a diagnosis of a clinically significant or progressive retinal disease in either eye.~* Subjects who were expected to require treatment with ocular or systemic corticosteroids.~* Subjects who were in need of any other topical or systemic treatment of OAG or OHT.~* Subjects with an anticipated need to initiate or modify medication (systemic or topical) that was known to affect IOP during the study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BOL-303259-X (Type: EXPERIMENTAL): ophthalmic solution
- Latanoprost (Type: ACTIVE_COMPARATOR): ophthalmic solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of MR-107A-02 in the Treatment of Post Surgical Dental Pain.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females ≥18 years of age.~2. Requirement for dental surgery for extraction of ≥2 third molars, at least 1 of which involves partial or complete mandibular bony impaction.~3. Pain Intensity (PI) using a Numeric Pain Rating Scale (NPRS) ≥5 during the 5 hours following the end of surgery in the eligibility assessment as well as in the baseline assessment immediately pre-dosing.~4. Rating of moderate or severe pain on a 4-point categorical pain rating scale (i.e., none, mild, moderate, severe) during the 5 hours following the end of surgery.~Exclusion Criteria:~1. Previously dosed with MR-107A-02.~2. Subject with known hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs).~3. Active GI bleeding or a history of peptic ulcer disease, active inflammatory bowel disease, e.g., Crohn's Disease or ulcerative colitis,or bleeding disorders that may affect coagulation.~4. Moderate or severe hypertension, prior stroke or transient ischemic attack.~5. Use of any investigational drug within 28 days, or 5 half-lives, prior to consent whichever is longer.~6. Use of medications with the potential to interact with MR-107A-02.~7. Other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MR-107A-02 1.25 mg twice in a 24 hour period (Type: EXPERIMENTAL): Oral tablet, one day of dosing
- MR-107A-02 5 mg twice in a 24 hour period (Type: EXPERIMENTAL): Oral tablet, one day of dosing
- MR-107A-02 15 mg twice in a 24 hour period (Type: EXPERIMENTAL): Oral tablet, one day of dosing
- Placebo twice in a 24 hour period (Type: PLACEBO_COMPARATOR): Oral tablet, one day of dosing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fecal Microbial Transplantation in Treatment of Irritable Bowel Syndrome; a Double Blinded Placebo Controlled Trial.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria for patients:~* Patients with IBS-D according to Roma 3 criteria~Exclusion Criteria for patients:~* Immunomodulating medication~* Nocturnal abdominal pain~* Constant abdominal pain~* Alarm symptoms like rectal bleeding, weight loss, nightsweats~* Symptomatic heart/vascular/lung disease~* Renal failure~* Known food allergy~* Microscopic/collagenous colitis~* non-compliant~* BMI \<18~Inclusion criteria for donors:~* healthy volunteers~Exclusion criteria for donors~* Tattoos, imprisoning or piercing last 3 months~* Any history of chronic diarrhoea, constipation, inflammatory bowel disease, irritable bowel disease, colorectal polyps or cancer, immunosuppression, morbid obesity, metabolic syndrome, atopica, or fatigue~* positive test for hepatitis B, C, HIV, treponema pallidum~* sexual high risk habits~* antibiotic treatment in the past 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Fecal transplantation (Type: EXPERIMENTAL): Fecal transplantation of freshly prepared feces from healthy donor. Application by colonoscope in proximal half of colon.
- Placebo fecal transplantation (Type: PLACEBO_COMPARATOR): Sham transplant subject's own feces. Application by colonoscope in proximal part of colon.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single Center, Randomized Controlled Clinical Trail

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 1.Diagnosed with HCC according to the Primary liver cancer diagnosis and treatment practices published by the Ministry of Health in 2011 China~* 2.A Karnofsky Performance Status (KPS) score ≥70 points~* 3.Age between 18 and 70 years~* 4.Child-Pugh classA or B (class B patients had scores no greater than 7 points). In addition, the baseline laboratory tests had to meet the following criteria: white blood cells (WBCs) ≥1.5 × 109/L, platelets ≥50 × 109/L, hemoglobin ≥80 g/L, serum aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 2 x the upper limit of normal (ULN), serum creatinine ≤ 1.5 x ULN, an international normalized ratio (INR)\<1.5 or prothrombin time \< the ULN + 4 seconds, albumin ≥30 g/L, and total bilirubin ≤34mmol/L~* 5.Patients with advanced hepatocellular carcinoma who failed first-line therapy with surgery，radiofrequency ablation~Exclusion Criteria:~* 1.Pugh Child-Pugh Grade C, or with massive ascites or had a history of hepatic encephalopathy, or previous history of gastrointestinal bleeding~* 2.Poor general condition or cachexia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Celecoxib group (Type: EXPERIMENTAL): Patients were treated with sorafenib taking capsules celecoxib (Celebrex) at the same time, 200mg/day, last 6 months
- Control group (Type: ACTIVE_COMPARATOR): Patients take sorafenib only.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: HCG Versus Spontaneous LH in Intrauterine Insemination (IUI ) Cycles

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* age ≤ 36 years,~* regular menstrual cycles,~* body mass index (BMI) between 18 and 29 kg/m²,~* basal levels of FSH (≤ 12 IU/l),~* estradiol (≤ 80 pg/ml) and progesterone (≤ 1.6ng/ml) on day one of the cycle, normal hysterosalpingography (maximum 3 months prior starting the cycle).~* The use of donor sperm was also accepted as inclusion criteria.~Exclusion Criteria:~* PCOS~* endometriosis

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 36 Years
- Healthy Volunteers: t

Study Arms:
- spontaneous LH (Type: OTHER): None
- HCG (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete